Novartis' 'full-court press' key to ensuring rapid Zolgensma access
Test Achats porte plainte contre un médicament à 2 millions d'euros
Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge
Novartis releases long-term data for SMA gene therapy
Novartis Lauds Quebec's Move to Reimburse SMA Patients for Zolgensma
Zolgensma Launch “On Track,” but Significant Challenges Remain - Bionest
EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters
$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian
Novartis Media Release guide - August 2019
Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA
Zolgensma gene therapy for sma patients: long-term data
Novartis releases long-term Zolgensma data
Zolgensma: Progress Report on the World's Most Expensive Drug | The Smart Cube
Novartis faces serious delays in registration of Zolgensma in Russia
R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence
Four Takeaways from the Zolgensma Pricing Storm
Novartis's SMA gene therapy Zolgensma to be available for NHS use - Pharmaceutical Technology
R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence
Novartis used faulty data for world's most expensive drug Zolgensma
Novartis Reveals Two Deaths Related to SMA Drug Zolgensma | BioSpace
FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association
Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve | Fierce Pharma
Path clears for Novartis's Zolgensma after FDA lifts longstanding hold
News Archive | Novartis
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor
